“Over-the-Wire” Device Treats Resistant High Blood Pressure
By HospiMedica International staff writers
Posted on 12 Feb 2013
A next-generation renal denervation device uses ultrasound energy for complete circumferential denervation more consistently and efficiently than the standard of care radiofrequency (RF) ablation catheter.Posted on 12 Feb 2013
The Paradise minimally invasive 2-mm diameter over-the-wire (OTW) ultrasound device is used for treating resistant high blood pressure in a three-fold approach; first, the device is designed to penetrate up to 8 millimeters into the tissue; second, the device delivers heat circumferentially, to target all of the renal nerves in one location; and third, this is achieved while simultaneously cooling the artery wall’s surface to protect the vessel.
Image: The Paradise OTW ultrasound device (Photo courtesy of ReCor Medical).
Treatment parameters of the second-generation device have been enhanced to reduce energy delivery to 30 seconds for maximizing cooling of the endothelium, and efficiently treating the nerves circumferentially. The Paradise 2 mm OTW ultrasound device is a product of ReCor Medical (Menlo Park, CA, USA), and has received the European Community CE marking of approval.
“Our unique approach is in stark contrast to RF, which is limited in its depth of penetration to just a few millimeters, due to inconsistent arterial wall contact, as well as its inability to heat circumferentially in any given location,” said Mano Iyer, CEO of ReCor Medical. “Renal nerves are actually much further at depth than previously thought, and run circumferentially around the renal arteries, which underscore the Paradise ultrasound advantage.”
Renal denervation is a, endovascular catheter based procedure for treating resistant hypertension. By applying energy pulses to the renal arteries, the nerves in the vascular wall (adventitia layer) can be denervated. This causes reduction of renal sympathetic afferent and efferent activity and blood pressure can be decreased. Early data from international clinical trials is promising, demonstrating an average blood pressure reduction of approximately 30 mm Hg at three-year follow up in patients with treatment-resistant hypertension.
Related Links:
ReCor Medical